Data gathered: December 21
AI Stock Analysis - Inovio Pharmaceuticals (INO)
Analysis generated October 29, 2024. Powered by Chat GPT.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing DNA immunotherapies and vaccines. The company’s principal research, development, and clinical capabilities are built around its DNA medicine platform, which is used to design and develop proprietary DNA medicines to treat cancers and infectious diseases. With a diverse pipeline of products in various stages of development, Inovio has positioned itself as a critical player in the biopharmaceutical sector, aiming for breakthroughs in vaccination and immunotherapy.
Stock Alerts - Inovio Pharmaceuticals (INO)
 |
Inovio Pharmaceuticals | December 19 Price is up by 6.2% in the last 24h. |
|
Inovio Pharmaceuticals | December 18 Price is down by -5.1% in the last 24h. |
|
Inovio Pharmaceuticals | December 17 Price is down by -5.6% in the last 24h. |
|
Inovio Pharmaceuticals | December 16 Price is down by -5.6% in the last 24h. |
Alternative Data for Inovio Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 22 | Sign up | Sign up | Sign up |
| Patents | 107 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 3 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,698 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 30 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 93,165 | Sign up | Sign up | Sign up |
| Twitter Followers | 17,316 | Sign up | Sign up | Sign up |
| Twitter Mentions | 497 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,040 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 34 | Sign up | Sign up | Sign up |
| Business Outlook | 23 | Sign up | Sign up | Sign up |
| Linkedin Employees | 218 | Sign up | Sign up | Sign up |
About Inovio Pharmaceuticals
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
| Price | $1.84 |
| Target Price | Sign up |
| Volume | 1,350,000 |
| Market Cap | $67M |
| Year Range | $1.78 - $13.07 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Wellington Management Group LLP Takes $379,000 Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)December 21 - ETF Daily News |
|
Inovio Pharmaceuticals Announces Pricing of $30 Million Public OfferingOn December 13, 2024, Inovio Pharmaceuticals, Inc. (NASDAQ: INO) disclosed the pricing details of their underwritten public offering of 10,000,000 shares of common stock and accomDecember 17 - ETF Daily News |
INOVIO Announces Pricing of $30 Million Public OfferingDecember 15 - Finnhub |
|
Inovio Pharmaceuticals : Announces Pricing of $30 Million Public Offering Form 8 KDecember 15 - Finnhub |
|
|
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $38.00December 14 - ETF Daily News |
 |
Inovio Pharmaceuticals: The Dangerous Allure Of A Falling KnifeDecember 14 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 8.6M | -8.6M | -25M | 0 | 0.000 |
| Q2 '24 | 1.4M | 10M | -8.8M | -32M | -31M | -1.190 |
| Q1 '24 | 630,000 | 11M | -9.9M | -30M | -30M | -1.310 |
| Q4 '23 | 730,000 | 10M | -9.5M | -25M | -27M | -1.120 |
| Q3 '23 | 2M | 20M | -18M | -34M | -36M | -0.130 |
Insider Transactions View All
| Zoth Lota S. filed to sell 52,716 shares at $0.6. June 5 '23 |
| Weiner David B. filed to sell 910,124 shares at $1.2. March 13 '23 |
| Weiner David B. filed to sell 904,291 shares at $1.3. February 28 '23 |
| Weiner David B. filed to sell 892,625 shares at $2.7. August 11 '22 |
| BENITO SIMON X filed to sell 75,305 shares at $2.3. July 20 '22 |
Similar companies
Read more about Inovio Pharmaceuticals (INO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Inovio Pharmaceuticals?
The Market Cap of Inovio Pharmaceuticals is $67M.
What is the current stock price of Inovio Pharmaceuticals?
Currently, the price of one share of Inovio Pharmaceuticals stock is $1.84.
How can I analyze the INO stock price chart for investment decisions?
The INO stock price chart above provides a comprehensive visual representation of Inovio Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Inovio Pharmaceuticals shares. Our platform offers an up-to-date INO stock price chart, along with technical data analysis and alternative data insights.
Does INO offer dividends to its shareholders?
As of our latest update, Inovio Pharmaceuticals (INO) does not offer dividends to its shareholders. Investors interested in Inovio Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Inovio Pharmaceuticals?
Some of the similar stocks of Inovio Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.